CORMEDIX INC (CRMD)

CorMedix Inc. Announces CMS Grants TDAPA to DefenCath

BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.

CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)

BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...

Noteworthy Thursday Option Activity: BTU, RIVN, CRMD

CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

BERKELEY HEIGHTS, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic...

CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

BERKELEY HEIGHTS, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic...

Commit To Buy CorMedix At $3, Earn 21.6% Annualized Using Options

Noteworthy Thursday Option Activity: ZION, CRMD, BALL

CorMedix (CRMD) Q4 2023 Earnings Call Transcript

CRMD earnings call for the period ending December 31, 2023.

CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern Time

CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024

BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2023, before the market opens on Tuesday, March 12, 2024, and will host a corporate update conference call at 8:30am Eastern Time.

CorMedix Inc. Announces Commercial and Reimbursement Updates

BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...

CorMedix Inc. Announces Commercial and Operational Updates

BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...

Commit To Purchase CorMedix At $3, Earn 28.6% Annualized Using Options

CorMedix Inc. Announces Appointment of Chief Legal Officer

BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...

CorMedix collaborates with The Leapfrog Group (NASDAQ:CRMD)

Biopharmaceutical company CorMedix partners with The Leapfrog Group to advance patient safety initiatives and promote shared accountability.

CorMedix Inc. Announces Partnership With The Leapfrog Group

– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog’s Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. ...

Noteworthy Wednesday Option Activity: TFIN, ZYXI, CRMD

CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

– First and only FDA-approved antimicrobial catheter lock solution in the U.S. – Company expects DefenCath to be available in Q1 2024 in the inpatient...

CorMedix stock jumps on FDA nod for DefenCath (NASDAQ:CRMD)

The FDA approval of CorMedix's (CRMD) DefenCath to lower infection risk in kidney disease patients on hemodialysis leads to a 35% surge in company shares. Read more here.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday!

CorMedix (CRMD) Q3 2023 Earnings Call Transcript

CRMD earnings call for the period ending September 30, 2023.

CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time...

CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023

BERKELEY HEIGHTS, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

BERKELEY HEIGHTS, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...

Commit To Buy CorMedix At $3, Earn 45.1% Annualized Using Options

CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...

CorMedix CEO buys shares worth $37.1k - filing (NASDAQ:CRMD)

CorMedix (CRMD) CEO Joseph Todisco disclosed in an SEC filing on Friday a purchase of 10,000 shares of the company at $3.71 per share, worth about $37,100.SEC...

CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology

BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...

CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath

BERKELEY HEIGHTS, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...